{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:38Z","timestamp":1789469138346,"version":"build-2803163510"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gansu Provincial Science and Technology Plan Project","award":["25JRRA1035"],"award-info":[{"award-number":["25JRRA1035"]}]},{"name":"Cuiying Science and Technology Innovation Program of the Second Hospital of Lanzhou University","award":["CY2024-QN-B03"],"award-info":[{"award-number":["CY2024-QN-B03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07113-x","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:24:18Z","timestamp":1781893458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax plus Idarubicin and cytarabine as frontline induction for newly diagnosed acute myeloid leukemia in young, fit adults: a real-world study"],"prefix":"10.1007","volume":"105","author":[{"given":"Chengcheng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuiLing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"7","key":"7113_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"24","key":"7113_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137\u20132145","journal-title":"Blood"},{"issue":"30","key":"7113_CR3","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.20.00572","volume":"38","author":"CC Chua","year":"2020","unstructured":"Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM et al (2020) Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol 38(30):3506\u20133517","journal-title":"J Clin Oncol"},{"issue":"17","key":"7113_CR4","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood.2024026700","volume":"145","author":"I Mantzaris","year":"2025","unstructured":"Mantzaris I, Goldfinger M, Uriel M, Shastri A, Shah N, Gritsman K et al (2025) Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study. Blood 145(17):1870\u20131875","journal-title":"Blood"},{"key":"7113_CR5","doi-asserted-by":"crossref","unstructured":"Naik A, Kataria B, Sharma V, Sharma A, Batra A, Bhatia K et al (2025) Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience. Haematologica 111(6):2141\u20132144","DOI":"10.3324\/haematol.2025.289048"},{"issue":"12","key":"7113_CR6","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 6(12):1890\u20131899","journal-title":"JAMA Oncol"},{"issue":"16","key":"7113_CR7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1080\/14656566.2025.2582022","volume":"26","author":"P Niscola","year":"2025","unstructured":"Niscola P, Catalano G, Pasqualini G, Piccioni D, Giovannini M, Noguera NI (2025) Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia. Expert Opin Pharmacother 26(16):1725\u20131739","journal-title":"Expert Opin Pharmacother"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07113-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07113-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07113-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:50Z","timestamp":1789465370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07113-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":7,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7113"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07113-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Ethics Committee of Lanzhou University second hospital (2025\u00a0A-1374) in accordance with the Declaration of Helsinki and local regulations. Informed consent to participate was obtained from all subjects and\/or their legal guardian(s).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all subjects and\/or their legal guardian(s) for publication of this case report and any accompanying images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"403"}}